Generic medicines have benefited millions of Americans and saved $1.5 trillion dollars in the past 10 years. And while much progress has been made, there are still too many off-patent medications that have few or no generic options.
With our Generics Access Plan we can help increase patient access to medicines by facilitating generics competition through new and revised standards, training and education, and collaborations with the FDA, industry representatives and others.
A recently published study by Johns Hopkins University found that drugs with a USP standard have approximately 50% more generic manufacturers in the U.S. than those without a standard. This increased competition was associated with reducing prescription drug costs.
We are committed to support FDA’s List of Off-Patent, Off-Exclusivity Drug Products without an Approved Generic (OPOE) to expedite greater access for important generic drug therapies and help ensure quality and scientific rigor during drug development and manufacturing.
The Call for Collaboration brings together engaged stakeholder organizations who are committed to increase access to quality generic medicines for legacy drugs without alternatives. Join this collaborative public health effort where public quality standards can help increase access to quality medicines for patients who need them.
Contact us at CallforCollaboration@usp.org to obtain additional information.
Explore what's behind our trust in generic medicine with pharmacy professor Inma Hernández, Ph.D., PharmD.
Jeremy Greene, M.D., Ph.D., Professor of Medicine and the History of Medicine, The Johns Hopkins School of Medicine, and author of Generic: The Unbranding of Modern Medicine, answers questions about the history of generic medicines.
